Compare Citius Pharmaceuticals Inc (CTXR) vs Taskus Inc (TASK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Taskus Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while Taskus Inc trades at $5.61 (market cap $530.70M). The key difference: Taskus Inc is far larger — about 36.3× Citius Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| CTXR | TASK | |
|---|---|---|
Market Cap | $14.64M | $530.70M |
Sector | Health | Technology |
52-Week High | $1.82 | $18.21 |
52-Week Low | $0.53 | $4.57 |
Enterprise Value | $10.86M | $926.40M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
TaskUs (TASK) trades at $5.62, up 3.88% with strong valuation metrics including P/E of 4.97 and P/S of 0.43. The company reported Q1 2026 earnings miss but maintains solid fundamentals with 8.7% net margin and 26.52% ROE. Technical indicators show mixed signals with bullish overall sentiment but bearish moving averages. Recent CFO appointment and robotaxi survey highlight growth initiatives.
The stock appears undervalued with 69% upside to consensus target of $9.50. Strong cash flow generation and improving debt-to-asset ratio (22.96% in 2025) support bullish case. Risks include competitive pressures and earnings volatility. Analyst consensus leans bullish with 55% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Taskus Inc
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to innovative and disruptive technology companies. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
Read more on TASK →
